Information Provided By:
Fly News Breaks for August 16, 2017
Aug 16, 2017 | 16:17 EDT
Evercore ISI analyst Josh Schimmer initiated Regeneron with an Outperform and a $605 price target.
News For REGN From the Last 2 Days
Jan 26, 2021 | 16:47 EDT
The major averages closed slightly lower as investors continue to monitor the virus and its mutations, the uneven pace of vaccine rollouts across the states and concern that the U. S... To see the rest of the story go to See Story Here
Jan 26, 2021 | 12:08 EDT
The major averages are mixed, but little changed, at midday as trading remains choppy and cautious. Investors are monitoring... To see the rest of the story go to See Story Here
Jan 26, 2021 | 09:55 EST
Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals with a $675 price target after the company released initial data on its antibody cocktail for Covid-19 prevention. This is the first look at its potential to serve as a passive vaccine in the prevention setting, Raymond tells investors in a research note. He believes results from the first 409 patients were "compelling," with confirmatory data from the Phase 3 study expected early next quarter. Raymond continues to model a "conservative scenario" for the drug with opportunities in the prevention setting serving as potential upside to his current estimates.
Jan 25, 2021 | 09:52 EST
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Outperform from Neutral at Credit Suisse with analyst Susan Roth Katzke saying the company with its Q4 results offered both targets and disclosure to increase clarity on the path to improved returns. 2. Salesforce (CRM) upgraded to Hold from Sell at Loop Capital with analyst Yun Kim saying the company's FY22 estimates of 17% organic revenue growth estimates vs. its previous 20% growth target have been "de-risked", and the recent checks suggest a "modest rebound" in its core business driven by increasing mid-sized deal activity. 3. Schlumberger (SLB) upgraded to Buy from Neutral at BofA with analyst Chase Mulvehill pointing to the rotation away from North American and into international energy names due to the growing uncertainty around the future of U.S. Oil and Gas regulatory environment under the Biden administration. 4. Regeneron (REGN) upgraded to Outperform from Market Perform at BMO Capital with analyst Matthew Luchini saying the company is "well positioned" heading into 2021 with potential for continued strong performance from Eylea, Dupixent and Libtayo and the ongoing Dupixent label expansion efforts and a combination-focused oncology pipeline providing additional growth opportunities. 5. ArcelorMittal (MT) upgraded to Overweight from Neutral at JPMorgan with analyst Luke Nelson saying the outlook for global steel equities has "markedly improved" after a "shaky" first half 2020 and "alpha can still be generated with stock selection" within the steel sector, Nelson tells investors in a research note. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.